

Smart Eye - Ramp-Up Delayed

Redeye estimates that Smart Eye's ramp-up of revenues will be delayed by 1-2 quarters. Also, due to the delay, Redeye sees a risk of Smart Eye needing to raise cash before turning profitable – but leading to a maximum of 10% dilution. Also, Redeye increases WACC from 9% to 10%. Redeye lowers its valuation range.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Smart Eye - Ramp-Up Delayed](#)